GeneriCo develops and markets niche generic pharmaceuticals, focusing on complex formulations overlooked by larger firms.
GeneriCo was founded with the mission to develop and market niche generic pharmaceuticals that are often neglected by mid-sized and large pharmaceutical companies. The company focuses on complex formulations that require advanced drug delivery technologies, making their pipeline unattractive to larger competitors and too challenging for smaller firms. GeneriCo aims to address gaps in the market by providing high-quality, technically challenging generic drugs.
Notable affiliated people and investors include industry experts with extensive experience in pharmaceutical development and investment. GeneriCo has achieved significant milestones in bringing complex generic formulations to market, thereby improving access to essential medications. Their impact lies in filling a critical void in the pharmaceutical industry by offering specialized generics that larger companies overlook, thereby enhancing patient care and treatment options.

Saptalis Pharmaceuticals
saptalis.com

Genzum Life Sciences
genzum.com

Solaris Pharma
solaris-pharma.com

Vitruvias Therapeutics
vitruvias.com

Nivagen Pharmaceuticals
nivagen.com
US Specialty Formulations

R K Pharma
rkpharmainc.com

Meitheal Pharmaceuticals
meithealpharma.com

Generian Pharmaceuticals
generian.com

Bionpharma
bionpharma.com

Pyros Pharmaceuticals

Continuity Pharma
Manhattan Pharmaceuticals

6S Pharma
6spharma.com

Handa Pharmaceuticals
handapharma.com

Leading Pharma
leadingpharma.com

Accuitis
accuitis.com

Auxilius Pharma
auxiliuspharma.com

Elite Pharmaceuticals
elitepharma.com
Generico's most recent funding round was for $1.5M (USD) in July 2015.
As of Jul 28, 2015, Generico has disclosed funding of $1.9M (USD).